Unraveling wasp sensitization in a patient with systemic mastocytosis by CAP-inhibition assay

Main Article Content

Helena Valero
Olga Luengo
Victoria Cardona
Javier Pereira
Moises Labrador-Horrillo

Keywords

CAP-inhibition, hymenoptera venom allergy, indolent systemic mastocytosis, REMA-score, venom immunotherapy

Abstract

Systemic mastocytosis (SM) is a clonal mast cell disorder that can lead to potentially severe anaphylactic reactions. Hymenoptera sting is one of the most frequent triggers of anaphylaxis in these patients, and diagnosis of indolent SM (ISM) without skin involvement (ISMs) is not rare. In this subgroup of patients, venom immunotherapy (VIT) is an effective treatment decreasing subsequent systemic reactions, and lifelong administration is recommended. An individualized diagnosis is necessary to offer the most adequate VIT, and molecular diagnosis (MD) may be useful to discriminate between primary sensitization and cross-reactivity. Nevertheless, other techniques such as ImmunoCAP inhibition assays may be necessary to identify the genuine sensitization to offer the most suitable VIT. We present a male patient with an anaphylactic reaction following several wasp stings. The patient was diagnosed with ISM, and allergy to both Polistes dominula and Vespula sp venom was confirmed. In this scenario, MD did not discriminate between a genuine double sensitization and venom cross-reactivity between both vespids. Thus, CAP-inhibition assay was performed. This case indicated the importance of an accurate diagnosis of hymenoptera venom allergy (HVA). It also highlights the usefulness of CAP-inhibition assays when MD fails to distinguish between genuine double Polistes-Vespula sensitization and cross-reactivity.

Abstract 42 | PDF Downloads 64 HTML Downloads 0 XML Downloads 2

References

1. Alvarez-Twose I, Matito A. Mastocytosis presenting as insect anaphylaxis: gender differences and natural history. Curr Opin Allergy Clin Immunol. 2019;19(5):468–474. 10.1097/ACI.0000000000000567

2. Bonadonna P, Bonifacio M, Lombardo C, Zanotti R. Hymenoptera allergy and mast cell activation syndromes. Curr Allergy Asthma Rep. 2016;16(1):5. 10.1007/s11882-015-0582-5

3. Pardanani A. Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2021;96(4):508–525. 10.1002/ajh.26118

4. Alfaya Arias T, Soriano Gómis V, Soto Mera T, Vega Castro A, Vega Gutiérrez JM, Alonso Llamazares A, et al. Hymenoptera allergy committee of the SEAIC.. Key issues in hymenoptera venom allergy: an update. J Investig Allergol Clin Immunol. 2017;27(1):19–31. 10.18176/jiaci.0123

5. Bilò MB, Pravettoni V, Bignardi D, Bonadonna P, Mauro M, Novembre E, Quercia O, et al. Hymenoptera venom allergy: management of children and adults in clinical practice. J Investig Allergol Clin Immunol. 2019;29(3):180–205.

6. Mueller HL. Further experiences with severe allergic reactions to insect stings. N Engl J Med. 195920;261:374–7. 10.1056/NEJM195908202610803

7. Morgado JM, Álvarez-Twose I, Matito A, Garcia-Montero AC, Teodosio C, Jara-Acevedo M, et al. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish network on mastocytosis (REMA) study on 122 patients. Br J Haematol. 2016;172(1):56–63. 10.1111/bjh.13789

8. Savi E, Peveri S, Makri E, Pravettoni V, Incorvaia C. Comparing the ability of molecular diagnosis and CAP-inhibition in identifying the really causative venom in patients with positive tests to Vespula and Polistes species. Clin Mol Allergy. 2016;14:3. 10.1186/s12948-016-0040-5

9. Straumann F, Bucher C, Wüthrich B. Double sensitization to honeybee and wasp venom: immunotherapy with one or with both venoms? Int Arch Allergy Immunol. 2000;123:268–274. 10.1159/000024453

10. Pardanani A. Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2021;96(4):508–525. 10.1002/ajh.26118